CN106987640A - PIK3CA detection in Gene Mutation primed probe and its kit - Google Patents
PIK3CA detection in Gene Mutation primed probe and its kit Download PDFInfo
- Publication number
- CN106987640A CN106987640A CN201710294686.3A CN201710294686A CN106987640A CN 106987640 A CN106987640 A CN 106987640A CN 201710294686 A CN201710294686 A CN 201710294686A CN 106987640 A CN106987640 A CN 106987640A
- Authority
- CN
- China
- Prior art keywords
- probe
- seq
- nucleotide sequence
- codon
- upstream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 title claims abstract description 138
- 238000001514 detection method Methods 0.000 title claims abstract description 54
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 39
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 title claims abstract description 26
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 title claims abstract description 23
- 238000006243 chemical reaction Methods 0.000 claims abstract description 42
- 108020004705 Codon Proteins 0.000 claims abstract description 34
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 30
- 230000035772 mutation Effects 0.000 claims abstract description 28
- 101150063858 Pik3ca gene Proteins 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 102200085788 rs121913279 Human genes 0.000 claims abstract description 7
- 102200085789 rs121913279 Human genes 0.000 claims abstract description 7
- 239000002773 nucleotide Substances 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- 230000000692 anti-sense effect Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 13
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 5
- 230000000171 quenching effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 108010033040 Histones Proteins 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 13
- 238000007403 mPCR Methods 0.000 abstract description 4
- 239000013615 primer Substances 0.000 description 51
- 239000002987 primer (paints) Substances 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 28
- 210000002381 plasma Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000004087 circulation Effects 0.000 description 8
- 108090000353 Histone deacetylase Proteins 0.000 description 7
- 102000003964 Histone deacetylase Human genes 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011304 droplet digital PCR Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000015616 Histone Deacetylase 1 Human genes 0.000 description 1
- 108010024124 Histone Deacetylase 1 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000012732 spatial analysis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of PIK3CA detection in Gene Mutation primed probe and its kit, kit includes digital pcr premixed liquid, droplets stable agent and the primed probe mixed liquor for being used to prepare digital pcr reaction solution；Primed probe mixed liquor includes the upstream and downstream primer A and mutant probe A for being used to detect the 542nd codon E542K sites, upstream and downstream primer B and mutant probe B for detecting the 545th codon E545K sites, for detecting upstream and downstream primer C, the probe C of the 1047th codon H1047L site mutations of the 1047th codon and the probe D of the 1047th codon H1047R site mutations.The PIK3CA gene mutation detection kits sensitivity and specificity of the present invention are high, and sample requirements are few, can carry out multiplex PCR detection exactly with rapid and convenient.
Description
Technical field
The present invention relates to a kind of primer of detection PIK3CA gene mutations, probe and detection product, belong to biotechnology neck
Domain.
Background technology
Research has been found that to be existed in a variety of human cancers (colon cancer, breast cancer, the cancer of the brain, liver cancer, stomach cancer and lung cancer etc.)
PIK3CA amplification, missing and somatic mutation, research discovery, the PIK3CA generation being mutated not only with human malignancies
Development it is relevant, and with tumour by stages, classification and prognosis also have substantial connection.Therefore, in detection tumor patient different phase
PIK3CA is mutated, and patient's judging prognosis is had great significance
Exploring patient PIK3CA resistance mechanisms and prediction prognosis turns into a feasible approach, and clear and definite tumour is thin now
Born of the same parents understand released dna and enter the circulatory system so that by way of " liquid biopsy ", can be specific to early stage and late tumor patient
Nucleotide sequence analyzed, be a kind of Noninvasive detection oncogene and clinical therapeutic efficacy a kind of method, and
Patient is higher to the acceptance of Noninvasive sample collection mode.
But it is due to that cfDNA contents are low in most people serum/plasma, in tumour early stage, ctDNA only accounts for total free
The 0.01% of DNA, and the reason such as cfDNA fragments are relatively small, at present the clinical detection to tumor-related gene be mainly PCR sequencing PCR
With ARMS methods, and do not apply to.Therefore, ctDNA detection is accomplished by a kind of more special technology sensitiveer than conventional method.Use
The relatively low conventional method detection of sensitivity can only find tumour variation of the subset of patients before particular treatment is received, using Gao Ling
It can be found that the carrying saltant type patient of higher proportion if sensitivity method (such as dPCR) is detected.In terms of digital pcr is due to sensitivity
Advantage, by unimolecule amplification low-abundance gene signal is distinguished from complex background, available for disease or virus
Early diagnosis or curative effect monitoring.Digital pcr technology unimolecule amplification after to sample DNA accurate quantification, with than other PCR
Higher measurement accuracy.
The sensitivity of digital pcr depends primarily on 2 main aspects：Efficiency and specific detection that nucleic acids in samples is extracted
The sensitivity of system, both determine the detection sensitivity of target sequence together.Droplet type digital pcr detects extremely low copy number sample
Its testing result of this when is unstable, it is necessary to repeatedly parallel laboratory test.Due to the limitation of hardware device, it is difficult to be difficult to realize multiple sites
While detect, and dPCR Multiple detection systems are limited to the length of pcr amplification product, and the design to TaqMan probe has
Very high requirement.The present invention is improved from digital pcr detection architecture, improves stability and the sensitivity of digital pcr detection.
The content of the invention
High the technical problem to be solved in the present invention is to provide a kind of sensitivity and specificity, sample requirements are few, can be fast
Speed easily and accurately carries out the PIK3CA detection in Gene Mutation primed probe and its kit of multiplex PCR detection.
The present invention is that a kind of technical scheme for solving above-mentioned technical problem proposition is：A kind of PIK3CA detection in Gene Mutation is drawn
Physical prospecting pin, including for detecting the upstream and downstream primer A and mutant probe A in the 542nd codon E542K sites, for detecting the 545th
The upstream and downstream primer B and mutant probe B in codon E545K sites, for detect the 1047th codon upstream and downstream primer C, the
The probe C of the 1047 codon H1047L site mutations and probe D of the 1047th codon H1047R site mutations；
The nucleotide sequence of the sense primer A is as shown in SEQ ID No.1, the nucleotide sequence of the anti-sense primer A
As shown in SEQ ID No.2, the nucleotide sequence of the probe A as shown in SEQ ID No.3,
The nucleotide sequence of the sense primer B is as shown in SEQ ID No.4, the nucleotide sequence of the anti-sense primer B
As shown in SEQ ID No.5, the nucleotide sequence of the probe B as shown in SEQ ID No.6,
The nucleotide sequence of the sense primer C is as shown in SEQ ID No.7, the nucleotide sequence of the anti-sense primer C
As shown in SEQ ID No.8, the nucleotide sequence of the probe C is as shown in SEQ ID No.9, the nucleotides sequence of the probe D
Row are as shown in SEQ ID No.10.
Above-mentioned probe A, B, C, D have carried out LNA modifications.
The ultimate density of above-mentioned upstream and downstream primer A, B, C in reaction system is 0.1~0.3 μM/L, probe A, B, C, D
Ultimate density in reaction system is 0.15~0.30 μM/L.
Ultimate densities of the above-mentioned upstream and downstream primer A in reaction system is 0.19 μM/L, and the upstream and downstream primer B is in reaction
Ultimate density in system is 0.2 μM/L, and ultimate densities of the upstream and downstream primer C in reaction system is 0.19 μM/L, institute
State the ultimate density of probe A, B, C, D in reaction system be respectively 0.22 μM/L, 0.19 μM/L, 0.21 μM/L, 0.18 μM/L.
Above-mentioned probe A, B, C, D 5 ' ends are provided with reporter fluorescence group, and 3 ' ends are provided with quenching fluorescence group.
The present invention is that a kind of technical scheme for solving above-mentioned technical problem proposition is：A kind of above-mentioned primed probe of use
PIK3CA detection in Gene Mutation products.
The present invention is that a kind of technical scheme for solving above-mentioned technical problem proposition is：A kind of PIK3CA detection in Gene Mutation examination
Agent box, including for preparing digital pcr premixed liquid, droplets stable agent and the primed probe mixed liquor of digital pcr reaction solution；
The primed probe mixed liquor includes upstream and downstream primer A and the mutation for being used to detect the 542nd codon E542K sites
Probe A, upstream and downstream primer B and mutant probe B for detecting the 545th codon E545K sites, for detecting the 1047th password
Upstream and downstream primer C, the probe C and the 1047th codon H1047R site mutations of the 1047th codon H1047L site mutations of son
Probe D；
The nucleotide sequence of the sense primer A is as shown in SEQ ID No.1, the nucleotide sequence of the anti-sense primer A
As shown in SEQ ID No.2, the nucleotide sequence of the probe A as shown in SEQ ID No.3,
The nucleotide sequence of the sense primer B is as shown in SEQ ID No.4, the nucleotide sequence of the anti-sense primer B
As shown in SEQ ID No.5, the nucleotide sequence of the probe B as shown in SEQ ID No.6,
The nucleotide sequence of the sense primer C is as shown in SEQ ID No.7, the nucleotide sequence of the anti-sense primer C
As shown in SEQ ID No.8, the nucleotide sequence of the probe C is as shown in SEQ ID No.9, the nucleotides sequence of the probe D
Row are as shown in SEQ ID No.10.
Above-mentioned probe A, B, C, D have carried out LNA modifications；Described upstream and downstream primer A, B, C are final dense in reaction system
Degree is 0.1~0.3 μM/L, and the ultimate density of probe A, B, C, D in reaction system is 0.15~0.30 μM/L；It is described to visit
Pin A, B, C, D 5 ' ends are provided with reporter fluorescence group, and 3 ' ends are provided with quenching fluorescence group.
Above-mentioned PIK3CA gene mutation detection kits also include histone deacetylase solution, and the digital pcr is pre-
Mixed liquid includes archaeal dna polymerase, ultra-pure water, dNTPs mixed liquors, reference fluorescent ROX and buffer solution；Wrapped in the droplets stable agent
Include mineral oil.
During above-mentioned PIK3CA gene mutation detection kits reaction, reaction system includes the volume of digital pcr premixed liquid 10,
The volume of primed probe mixed liquor 2, the volume of droplets stable agent 2, the volume of template 1, sterilize the volume of ultra-pure water 5, the use of the template
Concentration is 0.1ng/ul~1ng/ul.
The present invention has positive effect：
1) PIK3CA gene mutation detection kits of the invention are different from conventional multi-primerses design principle, of the invention
Product length and primer length are shorter, and carry out special modification to primer and probe, improve for mutational site and wild
The specificity of the respective probe in type site, reaches the purpose of probe and target sequence specific binding, detection architecture is optimized so that this
The sensitivity of invention is 0.01%, and specificity is 100%, and the sample of lower mutation abundance can be detected.
2) PIK3CA gene mutation detection kits of the invention can also carry out multiplex PCR except being outside one's consideration with ultra-high sensitive
Analysis.4 re-detections are reached by the fluorescence signal and regulation concentration and probe concentration that design probe, 1 is detected by 1 original chip
PIK3CA sudden change samples are changed into 1 chip and detect 4 PIK3CA sudden change samples, and testing cost saves 50-100 members, greatly drop
Low cost.Quick, economic, sensitive detection is realized to mutation in the case of high flux sample.
3) PIK3CA gene mutation detection kits of the invention to the sample extracting of reaction system, probe modification mode and
Program is optimized, and sample process process optimization avoids harmful effect of the pre-treatment step to testing result accuracy, probe
Optimization is prevented effectively from the suppression between multiplex PCR probe and causes amplification efficiency unstable, it is ensured that in same reaction system
Carry out the stability of 4 re-detections.The combination of ddPCR and Multiple techniques improves the flux of genetic analysis so that can suffer from from each
More information is obtained in person's sample.Patient is higher to the acceptance of Noninvasive sample collection mode, absolute by the kit
It is quantitative that tumor patient has been carried out time and spatial analysis, change the sampling mode in Tumor mutations phase analysis, can be effective
CtDNA levels (copy number of mutation allele in per ml blood plasma) performance of ground monitoring tumor patient, can not only be from PIK3CA
It is mutated " having " or "None" is mutated the difference of matter, to " many " or the amount difference of " few " mutation, treatment is reacted in time, so as to influence
The selection and decision of therapeutic scheme, more preferably clinical application provide theoretical foundation.
Embodiment
The present invention is specifically described below by embodiment, it is necessary to it is pointed out here that be that following examples are only used
It is further described in the present invention, it is impossible to be interpreted as limiting the scope of the invention, person skilled in art can
To make some nonessential modifications and adaptations to the present invention according to the invention described above content.In following embodiments, if not specially
Show, reagent used is that analysis is pure, and agents useful for same can be obtained from commercial channel.The experiment of unreceipted actual conditions in text
Method, what the Science Press generally write according to normal condition such as J. Pehanorm Brookers etc. published for 2002《Molecular cloning is real
Test guide》Condition described in one book, or according to the condition proposed by manufacturer.Unless otherwise defined, the institute used in text
There is specialty identical with meaning known to one skilled in the art with scientific words.In addition, it is any similar to described content or
Impartial method and material all can be applied in the present invention.
First, the composition of kit.
The PIK3CA gene mutation detection kits of the present embodiment, including digital pcr premixed liquid, droplets stable agent, primer
Probe mixed liquor, histone deacetylase solution and positive control.Each composition of kit is as shown in table 1.
The Kit components table of table 1
| Composition | Packing | Reagent Company |
| Digital pcr premixed liquid | 1 pipe | Life technologies |
| Droplets stable agent | 1 pipe | Raindance technologies |
| Primed probe mixed liquor | 1 pipe | Hundred power lattice |
| Positive control | 1 pipe | —— |
| Histone deacetylase | 1 pipe | Beijing Suo Laibao Science and Technology Ltd |
Reagent constituents is described as follows in above-mentioned table 1：
1) main component of digital pcr premixed liquid includes archaeal dna polymerase, ultra-pure water, dNTPs mixed liquors, reference fluorescent
ROX, buffer solution etc. (are provided, article No. by Life technologies companies：1508099).
2) main component of droplets stable agent is mineral oil, (is provided by Raindance technologies companies, goods
Number：30-00826), main function is that reaction system is formed Water-In-Oil droplet by droplet processing procedure.
3) primed probe mixed liquor includes being used to detect PIK3CA genes the 542nd, 545, the primer of 1047 codons and spy
Pin, upstream and downstream primer A and mutant probe A namely for detecting the 542nd codon E542K sites, for detecting that the 545th is close
The upstream and downstream primer B and mutant probe B in numeral E545K sites, for detect the 1047th codon upstream and downstream primer C, the
The probe C of the 1047 codon H1047L site mutations and probe D of the 1047th codon H1047R site mutations.
The present embodiment has carried out LNA modifications to probe A, B, C, D.A LNA base is introduced i.e. in oligonucleotide probe,
And the specificity of optimal fusing point (Tm) and hybridization is adjusted by adjusting the position of LNA bases within the probe.After modification
Probe has higher Tm values, more preferably can be combined with mutagenesis template, the real-time quantitative PCR probe after modification, length is shorter, can
To increase the flexibility of design, cross the mutant probe of LNA modifications has more preferable saltant type to have more preferable sub-clustering to imitate to saltant type
Really.
According to the requirement of instrument and Multiple experiments, certain specific mutant form is needed with two different fluorescence labelings
Taqman probes, are marked to the end of Taqman probes 5 ' using two kinds of fluorescence of VIC and FAM, use MGB quenching groups pair
The end of Taqman probes 3 ' is marked.If the design of primer and probe is improper, the selection to crucial target sequence is directly affected,
The sensitivity and specificity of PCR detections are reduced, or even are fallen flat.Thus, it is necessary to there is sufficient understanding to extension increasing sequence, and advise
Model PCR Lab operating technology, uses identical sense primer and anti-sense primer for wild and mutation, prevents due to primer mistake
Interfere more, reduce the sensitivity of detection.
Probe A and probe B 5 ' end fluorescence labelings are that FAM, probe C and probe D 5 ' end fluorescence labelings are VIC,
When detection template (DNA profiling) is undergone mutation, corresponding detection probe has VIC fluorescence signals or FAM fluorescence signals.
4) histone deacetylase is provided by Beijing Suo Laibao Science and Technology Ltd, according to product description that enzyme is dilute
Release to 10ug ml, every milliliter of serum or blood plasma add 10ul dilutions.
5) positive control from carry PIK3CA gene mutations positive cell strain (including the 542nd, 545,1047 passwords
Saltant type including son), the DNA of saltant type and wild type PIK3CA genes is proportionally 1:100.
2nd, primed probe is designed.
Because the length of tumour dissociative DNA is very short, length≤180bp, the cracking of normal cell can discharge largely in blood
DNA, further reduction ctDNA abundance.Nuclease can also influence the stability of ctDNA in blood so that partial target piece
Duan Xulie may be shorter, if the amplified production of design primer is long, leading mutagenic sequence can not detect, the present invention
Product length is detected according to changing, it is found that the longer product mutation recall rate of shorter product mutation recall rate has bigger advantage,
It is more beneficial for realizing the detection of PIK3CA mutation.The primed probe length that the present invention is designed be 14~18bp, product length 50~
80bp, prevents from causing Positive rate to reduce because amplified production amplification is long, as shown in table 2.
The primer probe sequence table of table 2
| Position | Detect classification | Seq No. | Sequence(5’—3’) |
| E542K | Sense primer A | 1 | CAAAGAACAGCTCA |
| E542K | Anti-sense primer A | 2 | TAGCACTTACCTGTGA |
| E542K | Probe A | 3 | AGATCCTCTCTCTAA |
| E545K | Sense primer B | 4 | TGACAAAGAACAGCT |
| E545K | Anti-sense primer B | 5 | TGTGACTCCATAGAAA |
| E545K | Probe B | 6 | ATCACTGAGGAGGA |
| 1047 codons | Sense primer C | 7 | CTGAGCAAGAGGCTTT |
| 1047 codons | Anti-sense primer C | 8 | TGGAAGATCCAATCCA |
| H1047L | Probe C | 9 | ATGAATGATGCATA |
| H1047R | Probe D | 10 | GATGATGCAGATCA |
Primed probe has the synthesis of the Li Ge Bioisystech Co., Ltd of Shanghai hundred, and work is diluted to by dry powder according to primer specification
Make mother liquor, then detection working solution is configured to by mother liquor, primer and probe mixed liquor is by mother liquor addition sterilizing ultra-pure water dilution
Into.
Too high concentration and probe concentration can improve the probability with wild-type template mispairing, to meet during multiple digital pcr design
Need, according to different fluorescence labelings, and by adjusting concentration and probe concentration so that the drop of different mutation types is able to put down in two dimension
Distinguished in face.For detect ultimate densities of the upstream and downstream primer A in reaction system of the 542nd codon for 0.1~0.3 μM/
L, end reaction concentration preferably is 0.19 μM/L；For detecting the upstream and downstream primer B of the 545th codon in reaction system
Ultimate density is 0.1~0.3 μM/L, and end reaction concentration preferably is 0.2 μM/L；For detecting above and below the 1047th codon
It is 0.1~0.3 μM/L to swim ultimate densities of the primer C in reaction system, and end reaction concentration preferably is 0.19 μM/L；Probe
The ultimate density of A, B, C, D in reaction system is 0.15~0.30 μM/L, preferred end reaction concentration is respectively 0.22 μM/
L、0.19μM/L、0.21μM/L、0.18μM/L。
The application method of three kits.
1st, sample DNA is extracted
DNA sources can be serum/plasma, blood plasma, peripheral blood, mucous membrane of mouth etc..Gather the serum/plasma of tumor patient
Sample 5ml, high speed centrifugation separates supernatant, obtains serum/plasma.The serum/plasma STb gene provided with German Qiagen companies
Extracts kit (article No.：55114), the dissociative DNA in patients serum/blood plasma is extracted according to kit operational manual.Obtain
After serum/plasma sample dissociative DNA, pass through Thermo-Fisher companies3.0 nucleic acid-protein fluorescent quantitation instruments, are determined
Serum/plasma sample dissociative DNA concentration and purity, -20 DEG C of preservations.
Because normal cell etc. can be cracked in the blood after blood sampling in blood, substantial amounts of DNA is discharged, reduction ctDNA's is rich
Degree, nuclease can also influence the stability meeting of ctDNA in blood, cause both sides to influence on ctDNA detection, increase
The difficulty of ctDNA detections.The present embodiment, due to that can not carry out subsequent detection to sample in time, is dividing for a large amount of detection samples
Histone deacetylase (SIR2 enzymes) is added in the DNA sample after blood plasma or extracting from after, ensure that ctDNA's is steady
It is qualitative, and enzyme inactivates at high temperature, has no effect on follow-up amplification experiment.
2nd, prepared by digital pcr reaction solution
PCR reaction systems in table 3, take 20 μ l digital pcr premixed liquid in kit, 4 μ l primed probe to mix
Liquid is closed, 2ul template, 4 μ l droplets stable agent is added, sterilizing ultra-pure water is added and mends to 40 μ l, digital pcr reaction response is made
Liquid, prepares quantitative reaction system, and vibration is mixed, and centrifuges bubble removing.Template refers to the sample DNA after serum/plasma Sample Dilution
And negative control, negative control is autoclaving water.
Table 3PCR reaction system tables
| Reacted constituent | Add concentration | Add volume |
| Digital pcr premixed liquid | 2× | 20ul |
| Primed probe mixed liquor | --- | 4ul |
| Droplets stable agent | 10× | 4ul |
| Template | 0.1ng/ul~10ng/ul | 2ul |
| ddH2O | to 40ul |
3rd, PCR reacts droplet and prepared
Digital pcr mixed liquor is fabricated to the micro- reaction drops of PCR, 500~8,000,000 Water-In-Oil drops are formed.This experiment
Reaction system by drop generator formation picoliters level size Water-In-Oil droplet, DNA molecular mixture is distributed to
In the droplet of million, each reative cell averagely contains one or zero target molecule.Droplet generation plate is put into 8 passage droplets
In maker, the drop generators RainDrop Source produced with Raindance companies carry out droplet processing to sample.
4th, PCR is expanded
Performing PCR amplification is entered to the droplet of generation using the PCR amplification instrument of Bo companies.Response procedures are as follows：Pre-degeneration rank
94 DEG C of the condition of section, 8min；1 circulation；94 DEG C of 10s, 52 DEG C of 10s, 36 circulations；94 DEG C, 8min, 1 circulation；12℃
20min, 1 circulation；4 DEG C, insulation.
5th, droplet is detected
After PCR reactions terminate, 8 unions are placed in droplet analyzer, the droplet analyzer produced with Raindance companies
RainDrop Sense are analyzed the fluorescence signal of each droplet the droplet containing fluorescence signal labeled as 1, without fluorescence
Signal is labeled as 0, then droplet is counted, and software is automatically analyzed.Because digital pcr is a kind of terminal analysis method, if target molecule
Without discretization well, such as some droplets include multiple target nucleic acid molecules, then the result obtained in theory will be inaccurate,
Therefore introduce Poisson probability distribution function and be used to analyze data.
Poisson distribution formula is as follows：
According to the coefficient of dilution of droplet sum, the droplet number containing fluorescence signal and sample, the ctDNA water of sample can obtain
The abundance of flat and corresponding PIK3CA gene mutations.The ctDNA levels of sample represent the copy of every milliliter of blood plasma allelic
Number, gene mutation abundance represents the mutant copies number of PIK3CA genes in peripheral blood genome, and mutation includes the 542nd, 545 and
The mutation of 1047 codons.
Comparative example 1
In order to improve the sensitivity of detection, those skilled in the art have carried out contrast experiment, the detection examination of this comparative example
Agent box, remainder is same as Example 1, and difference is：
1) primed probe design is using conventional primed probe design principle, and design primer length is 18~25bp, probe
Length is 20~30bp, and product length is 80~150bp, and probe does not carry out LNA modifications, primer probe sequence such as table 4
It is shown.
The custom primer probe sequence table of table 4
2) histone deacetylase dilution is not added in sample extraction step.
3) PCR amplification programs are：95 DEG C of the condition in pre-degeneration stage, 10min；1 circulation；94 DEG C of 10s, 52 DEG C of 15s, 60
DEG C 45s, 36 circulations；98 DEG C, 10min, 1 circulation；12 DEG C of 30min, 1 circulation；4 DEG C, insulation.
Take 50 samples that embodiment 1 is respectively adopted and the kit of comparative example 1 is detected, the PIK3CA bases of 50 samples
Because mutation abundance as shown in table 5 and table 6.
The comparative example 1 of table 5 detects the PIK3CA gene mutations abundance table (%) of 50
The embodiment 1 of table 6 detects the PIK3CA gene mutations abundance table (%) of 50
As a result show, use the positive rate of kit of comparative example 1 for the abundance of 6%, PIK3CA gene mutations
Average value is 1.6%；The positive rate of kit of embodiment 1 is used for the flat of the abundance of 12%, PIK3CA gene mutations
Average is 7.3%.
Comparative example 2
In order to optimize the detection kit of this comparative example, remainder is same as Example 1, and difference is：
1) probe does not carry out LNA modification.
2) histone deacetylase (SIR2 is added in the blood plasma after being separated when using or the DNA sample after extracting
Enzyme).
The positive sample of 20 PIK3CA gene mutations is taken, takes 20 samples that the examination of embodiment 1 and comparative example 2 is respectively adopted
Agent box is detected that the abundance of the PIK3CA gene mutations of 20 samples is as shown in table 7 and table 8.
The comparative example 2 of table 7 detects the abundance table (%) of the PIK3CA gene mutations of 20
The embodiment 1 of table 8 detects the abundance table (%) of the PIK3CA gene mutations of 20
Histone deacetylase is added in blood plasma after being separated during due to using or the DNA sample after extracting
High 5~10ng/ul of ctDNA concentration ratios comparative example 2 in (SIR2 enzymes), the sample serum of embodiment 1.Embodiment 1
The average value of the PIK3CA gene mutation abundance of the abundance ratio comparative example 2 of PIK3CA gene mutations is high by 4.1%.
Above-described embodiment is only intended to clearly illustrate example of the present invention, and is not the embodiment party to the present invention
The restriction of formula.For those of ordinary skill in the field, other differences can also be made on the basis of the above description
The change or variation of form.There is no necessity and possibility to exhaust all the enbodiments.And these belong to the essence of the present invention
Among the obvious changes or variations that god extends out is still in protection scope of the present invention.
SEQUENCE LISTING
<110>Shanghai Saian Biological Medical Technology Co., Ltd.
<120>PIK3CA detection in Gene Mutation primed probe and its kit
<130>Nothing
<160> 10
<170> PatentIn version 3.3
<210> 1
<211> 14
<212> DNA
<213>It is artificial synthesized
<400> 1
caaagaacag ctca 14
<210> 2
<211> 16
<212> DNA
<213>It is artificial synthesized
<400> 2
tagcacttac ctgtga 16
<210> 3
<211> 15
<212> DNA
<213>It is artificial synthesized
<400> 3
agatcctctc tctaa 15
<210> 4
<211> 15
<212> DNA
<213>It is artificial synthesized
<400> 4
tgacaaagaa cagct 15
<210> 5
<211> 16
<212> DNA
<213>It is artificial synthesized
<400> 5
tgtgactcca tagaaa 16
<210> 6
<211> 14
<212> DNA
<213>It is artificial synthesized
<400> 6
atcactgagg agga 14
<210> 7
<211> 16
<212> DNA
<213>It is artificial synthesized
<400> 7
ctgagcaaga ggcttt 16
<210> 8
<211> 16
<212> DNA
<213>It is artificial synthesized
<400> 8
tggaagatcc aatcca 16
<210> 9
<211> 14
<212> DNA
<213>It is artificial synthesized
<400> 9
atgaatgatg cata 14
<210> 10
<211> 14
<212> DNA
<213>It is artificial synthesized
<400> 10
gatgatgcag atca 14
Claims (10)
1. a kind of PIK3CA detection in Gene Mutation primed probe, it is characterised in that：Including for detecting the 542nd codon E542K
The upstream and downstream primer A and mutant probe A in site, upstream and downstream primer B and mutation for detecting the 545th codon E545K sites
Probe B, upstream and downstream primer C, the probe C of the 1047th codon H1047L site mutations and for detecting the 1047th codon
The probe D of 1047 codon H1047R site mutations；
The nucleotide sequence of the sense primer A is as shown in SEQ ID No.1, the nucleotide sequence such as SEQ of the anti-sense primer A
Shown in ID No.2, the nucleotide sequence of the probe A as shown in SEQ ID No.3,
The nucleotide sequence of the sense primer B is as shown in SEQ ID No.4, the nucleotide sequence such as SEQ of the anti-sense primer B
Shown in ID No.5, the nucleotide sequence of the probe B as shown in SEQ ID No.6,
The nucleotide sequence of the sense primer C is as shown in SEQ ID No.7, the nucleotide sequence such as SEQ of the anti-sense primer C
Shown in ID No.8, the nucleotide sequence of the probe C is as shown in SEQ ID No.9, the nucleotide sequence such as SEQ of the probe D
Shown in ID No.10.
2. PIK3CA detection in Gene Mutation primed probe according to claim 1, it is characterised in that：The probe A, B, C,
D has carried out LNA modifications.
3. PIK3CA detection in Gene Mutation primed probe according to claim 1, it is characterised in that：The upstream and downstream primer
The ultimate density of A, B, C in reaction system is 0.1~0.3 μM/L, the ultimate density of probe A, B, C, D in reaction system
It is 0.15~0.30 μM/L.
4. PIK3CA detection in Gene Mutation primed probe according to claim 3, it is characterised in that：The upstream and downstream primer
Ultimate densities of the A in reaction system is 0.19 μM/L, and ultimate densities of the upstream and downstream primer B in reaction system is 0.2 μ
The ultimate density of M/L, the upstream and downstream primer C in reaction system is 0.19 μM/L, and described probe A, B, C, D are in reaction system
In ultimate density be respectively 0.22 μM/L, 0.19 μM/L, 0.21 μM/L, 0.18 μM/L.
5. PIK3CA detection in Gene Mutation primed probe according to claim 1, it is characterised in that：The probe A, B, C,
D 5 ' ends are provided with reporter fluorescence group, and 3 ' ends are provided with quenching fluorescence group.
6. a kind of PIK3CA detection in Gene Mutation products using primed probe as claimed in claim 1.
7. a kind of PIK3CA gene mutation detection kits, it is characterised in that：Including the numeral for preparing digital pcr reaction solution
PCR premixed liquids, droplets stable agent and primed probe mixed liquor；
The upstream and downstream primer A and mutant probe A for being used to detect the 542nd codon E542K sites, for detecting that the 545th is close
The upstream and downstream primer B and mutant probe B in numeral E545K sites, for detect the 1047th codon upstream and downstream primer C, the
The probe C of the 1047 codon H1047L site mutations and probe D of the 1047th codon H1047R site mutations；
The nucleotide sequence of the sense primer A is as shown in SEQ ID No.1, the nucleotide sequence such as SEQ of the anti-sense primer A
Shown in ID No.2, the nucleotide sequence of the probe A as shown in SEQ ID No.3,
The nucleotide sequence of the sense primer B is as shown in SEQ ID No.4, the nucleotide sequence such as SEQ of the anti-sense primer B
Shown in ID No.5, the nucleotide sequence of the probe B as shown in SEQ ID No.6,
The nucleotide sequence of the sense primer C is as shown in SEQ ID No.7, the nucleotide sequence such as SEQ of the anti-sense primer C
Shown in ID No.8, the nucleotide sequence of the probe C is as shown in SEQ ID No.9, the nucleotide sequence such as SEQ of the probe D
Shown in ID No.10.
8. PIK3CA gene mutation detection kits according to claim 6, it is characterised in that：Described probe A, B, C, D
LNA modifications are carried out；The ultimate density of described upstream and downstream primer A, B, C in reaction system is 0.1~0.3 μM/L, probe
The ultimate density of A, B, C, D in reaction system is 0.15~0.30 μM/L；Described probe A, B, C, D 5 ' ends are provided with report
Fluorophor, 3 ' ends are provided with quenching fluorescence group.
9. PIK3CA gene mutation detection kits according to claim 6, it is characterised in that：Also include histone and take off second
Acylated enzyme solutions, the digital pcr premixed liquid include archaeal dna polymerase, ultra-pure water, dNTPs mixed liquors, reference fluorescent ROX and
Buffer solution；The droplets stable agent includes mineral oil.
10. PIK3CA gene mutation detection kits according to claim 6, it is characterised in that：During reaction, reaction system
Include the volume of digital pcr premixed liquid 10, the volume of primed probe mixed liquor 2, the volume of droplets stable agent 2, the volume of template 1, sterilizing
The volume of ultra-pure water 5, the concentration of the template is 0.1ng/ul~1ng/ul.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710294686.3A CN106987640A (en) | 2017-04-28 | 2017-04-28 | PIK3CA detection in Gene Mutation primed probe and its kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710294686.3A CN106987640A (en) | 2017-04-28 | 2017-04-28 | PIK3CA detection in Gene Mutation primed probe and its kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106987640A true CN106987640A (en) | 2017-07-28 |
Family
ID=59417302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710294686.3A Pending CN106987640A (en) | 2017-04-28 | 2017-04-28 | PIK3CA detection in Gene Mutation primed probe and its kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106987640A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108004317A (en) * | 2017-11-09 | 2018-05-08 | 上海赛安生物医药科技股份有限公司 | PIK3CA detection in gene mutation system and its kit |
| CN108315428A (en) * | 2018-04-13 | 2018-07-24 | 江西海普洛斯生物科技有限公司 | A kind of the primer combination of probe object and its detection method of detection PIK3CA genes E545K |
| CN109161594A (en) * | 2018-08-17 | 2019-01-08 | 中山大学达安基因股份有限公司 | A kind of method and its kit detecting BRAF gene mutation |
| CN109666747A (en) * | 2019-02-20 | 2019-04-23 | 天津脉络医学检验有限公司 | A kind of primer combination of probe object and its application |
| CN110029171A (en) * | 2019-06-11 | 2019-07-19 | 上海伯豪生物技术有限公司 | A kind of kit using stem ring primer detection PIK3CA gene mutation site |
| CN111334580A (en) * | 2020-04-16 | 2020-06-26 | 中山大学达安基因股份有限公司 | PIK3CA gene mutation detection kit |
| CN111500720A (en) * | 2020-04-16 | 2020-08-07 | 中山大学达安基因股份有限公司 | PIK3CA gene mutation detection method and kit thereof |
| CN114214412A (en) * | 2021-12-28 | 2022-03-22 | 普瑞斯新(上海)生物医疗科技有限公司 | PIK3CA gene and BRAF gene mutation multiplex detection primer probe and kit thereof |
| CN114959032A (en) * | 2022-05-24 | 2022-08-30 | 季华实验室 | Breast cancer HER2 abundance PIK3CA mutation detection probe set and kit |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015172085A3 (en) * | 2014-05-09 | 2015-12-30 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| CN106520931A (en) * | 2016-10-17 | 2017-03-22 | 上海赛安生物医药科技有限公司 | EGFR gene mutation detection primer probe and kit thereof |
-
2017
- 2017-04-28 CN CN201710294686.3A patent/CN106987640A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015172085A3 (en) * | 2014-05-09 | 2015-12-30 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| CN106520931A (en) * | 2016-10-17 | 2017-03-22 | 上海赛安生物医药科技有限公司 | EGFR gene mutation detection primer probe and kit thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张霞等: "沉默信息调节因子2与基因转录调控，465-468", 《中国寄生虫学与寄生虫病杂志》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108004317A (en) * | 2017-11-09 | 2018-05-08 | 上海赛安生物医药科技股份有限公司 | PIK3CA detection in gene mutation system and its kit |
| CN108315428A (en) * | 2018-04-13 | 2018-07-24 | 江西海普洛斯生物科技有限公司 | A kind of the primer combination of probe object and its detection method of detection PIK3CA genes E545K |
| CN109161594A (en) * | 2018-08-17 | 2019-01-08 | 中山大学达安基因股份有限公司 | A kind of method and its kit detecting BRAF gene mutation |
| CN109666747A (en) * | 2019-02-20 | 2019-04-23 | 天津脉络医学检验有限公司 | A kind of primer combination of probe object and its application |
| CN110029171A (en) * | 2019-06-11 | 2019-07-19 | 上海伯豪生物技术有限公司 | A kind of kit using stem ring primer detection PIK3CA gene mutation site |
| CN110029171B (en) * | 2019-06-11 | 2019-08-30 | 上海伯豪生物技术有限公司 | A kind of kit using stem ring primer detection PIK3CA gene mutation site |
| CN111334580A (en) * | 2020-04-16 | 2020-06-26 | 中山大学达安基因股份有限公司 | PIK3CA gene mutation detection kit |
| CN111500720A (en) * | 2020-04-16 | 2020-08-07 | 中山大学达安基因股份有限公司 | PIK3CA gene mutation detection method and kit thereof |
| CN114214412A (en) * | 2021-12-28 | 2022-03-22 | 普瑞斯新(上海)生物医疗科技有限公司 | PIK3CA gene and BRAF gene mutation multiplex detection primer probe and kit thereof |
| CN114214412B (en) * | 2021-12-28 | 2024-02-23 | 普瑞斯新(上海)生物医疗科技有限公司 | PIK3CA gene and BRAF gene mutation multiplex detection primer probe and kit thereof |
| CN114959032A (en) * | 2022-05-24 | 2022-08-30 | 季华实验室 | Breast cancer HER2 abundance PIK3CA mutation detection probe set and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106987640A (en) | PIK3CA detection in Gene Mutation primed probe and its kit | |
| CN104164516B (en) | A kind of primer based on the detection of Human colorectal carcinoma specific methylation and test kit | |
| CN101838683B (en) | Detection method of nucleotide mutation points of KRAS gene and/or BRAF gene | |
| CN107022619A (en) | KRAS gene mutation detection primer probe and its kit | |
| CN111020031A (en) | A method for the detection of tumor gene mutations using sequence-specific blockers combined with specific PCR procedures | |
| CN111748628A (en) | Primer and kit for detecting thyroid cancer prognosis related gene variation | |
| CN113025701B (en) | Early screening method and kit for non-alcoholic fatty liver disease susceptibility gene | |
| CN107513578A (en) | A kind of nucleic acid Mass Spectrometry detection method early sieved for lung cancer driving gene and tumor susceptibility gene | |
| CN107022620A (en) | N RAS detection in Gene Mutation primed probes and its kit | |
| CN107058548A (en) | C kit detection in Gene Mutation primed probes and its kit | |
| CN107022621A (en) | BRAF gene mutation detection primer probe and its kit | |
| US11535897B2 (en) | Composite epigenetic biomarkers for accurate screening, diagnosis and prognosis of colorectal cancer | |
| CN112553325B (en) | Guiding method and kit for personalized medicine gene of sufentanil | |
| EP2540838A1 (en) | Kit for quantitative detection of braf mutation | |
| WO2025051198A1 (en) | Method for screening for disease marker on the basis of methylation data | |
| CN114196740A (en) | Digital amplification detection method, detection product and detection kit for simultaneously identifying multiple gene types | |
| CN107904290A (en) | PDGFRA detection in gene mutation system and its kit | |
| CN113897429A (en) | Digital PCR detection method and application of human NRAS gene mutation | |
| CN118006769A (en) | Lung cancer related 7 gene methylation joint detection kit and use method thereof | |
| CN107937511A (en) | A kind of hypertrophic cardiomyopathy phenocopy（PRKAG2、GLA、TTR、LAMP2）Genetic detection kit | |
| CN108998528B (en) | Lung cancer diagnosis molecular marker lncRNA LINC00516, kit and application thereof | |
| CN112592972A (en) | Early screening method and kit for diffuse toxic goiter susceptibility genes | |
| Wei et al. | CRISPR/Cas13a-based single-nucleotide polymorphism detection for reliable determination of ABO blood group genotypes | |
| CN112410441A (en) | A method for identification of bee colony resistance to cystic larvae by using SNP marker KZ288479.1_95621 | |
| CN112831558B (en) | Early screening method and kit for Crohn disease susceptibility genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170728 |
|
| WD01 | Invention patent application deemed withdrawn after publication |